The type-1 ribosome-inactivating protein OsRIP1 triggers caspase-independent apoptotic-like death in HeLa cells

2021 ◽  
Vol 157 ◽  
pp. 112590
Author(s):  
Simin Chen ◽  
Cláudia Figueiredo Lóssio ◽  
Isabel Verbeke ◽  
Joost Verduijn ◽  
Bogdan Parakhonskiy ◽  
...  
Intervirology ◽  
2021 ◽  
Vol 64 (2) ◽  
pp. 88-95
Author(s):  
Bahar Sadegh Ehdaei ◽  
Ahmad Pirouzmand ◽  
Mehdi Shabani ◽  
Arezoo Mirzaei ◽  
Sharareh Moghim

<b><i>Introduction:</i></b> Herpes simplex viruses (HSVs) are widely distributed in the human population. HSV type 1 (HSV-1) is responsible for a spectrum of diseases, ranging from gingivostomatitis to keratoconjunctivitis, and encephalitis. The HSVs establish latent infections in nerve cells, and recurrences are common. Their frequent reactivation in elderly and immunosuppressed patients causes serious health complications. <b><i>Objectives:</i></b> Due to the growing resistance to its main drug, acyclovir, alternative treatments with different mechanisms of action are required. MicroRNAs regulate host and viral gene expression posttranscriptionally. Previous studies reported that mir-101-2 expression has widely participated in the regulation of HSV-1 replication. In this study, we investigate the effect of hsa-miR-101-1 in the replication of HSV-1. <b><i>Methods:</i></b> We found that transfection of miR-101-1 into HeLa cells could reduce effectively HSV-1 replication using plaque assay and real-time PCR methods. <b><i>Results:</i></b> We showed that overexpression of miR-10-1 produced less viral progeny and manifested a weaker cytopathic effect, without affecting cell viability. <b><i>Discussion/Conclusion:</i></b> This result can give us new insights into the control of HSV-1 infections.


2000 ◽  
Vol 275 (2) ◽  
pp. 481-487 ◽  
Author(s):  
Qiang Hao ◽  
Els J.M. Van Damme ◽  
Annick Barre ◽  
Alain Sillen ◽  
Pierre Rougé ◽  
...  

2019 ◽  
Vol 157 ◽  
pp. 121-127 ◽  
Author(s):  
Arsenij Kokorin ◽  
Christoph Weise ◽  
Simko Sama ◽  
Alexander Weng

1996 ◽  
Vol 242 (3) ◽  
pp. 585-591 ◽  
Author(s):  
Shigeo Yoshinari ◽  
Sadaki Yokota ◽  
Hiroshi Sawamoto ◽  
Shigehiro Koresawa ◽  
Minoru Tamura ◽  
...  

2021 ◽  
Vol 22 (16) ◽  
pp. 8964
Author(s):  
Sara Ragucci ◽  
Daniela Bulgari ◽  
Nicola Landi ◽  
Rosita Russo ◽  
Angela Clemente ◽  
...  

Quinoin is a type 1 ribosome-inactivating protein (RIP) we previously isolated from the seeds of pseudocereal quinoa (Chenopodium quinoa) and is known as a functional food for its beneficial effects on human health. As the presence of RIPs in edible plants could be potentially risky, here we further characterised biochemically the protein (complete amino acid sequence, homologies/differences with other RIPs and three-dimensional homology modeling) and explored its possible defensive role against pathogens. Quinoin consists of 254 amino acid residues, without cysteinyl residues. As demonstrated by similarities and homology modeling, quinoin preserves the amino acid residues of the active site (Tyr75, Tyr122, Glu177, Arg180, Phe181 and Trp206; quinoin numbering) and the RIP-fold characteristic of RIPs. The polypeptide chain of quinoin contains two N-glycosylation sites at Asn115 and Asp231, the second of which appears to be linked to sugars. Moreover, by comparative MALDI-TOF tryptic peptide mapping, two differently glycosylated forms of quinoin, named pre-quinoin-1 and pre-quinoin-2 (~0.11 mg/100 g and ~0.85 mg/100 g of seeds, respectively) were characterised. Finally, quinoin possesses: (i) strong antiviral activity, both in vitro and in vivo towards Tobacco Necrosis Virus (TNV); (ii) a growth inhibition effect on the bacterial pathogens of plants; and (iii) a slight antifungal effect against two Cryphonectria parasitica strains.


Toxins ◽  
2018 ◽  
Vol 10 (8) ◽  
pp. 335 ◽  
Author(s):  
Wei-Wei Shi ◽  
Kam-Bo Wong ◽  
Pang-Chui Shaw

Trichosanthin (TCS) is an RNA N-glycosidase that depurinates adenine-4324 in the conserved α-sarcin/ricin loop (α-SRL) of rat 28 S ribosomal RNA (rRNA). TCS has only one chain, and is classified as type 1 ribosome-inactivating protein (RIP). Our structural studies revealed that TCS consists of two domains, with five conserved catalytic residues Tyr70, Tyr111, Glu160, Arg163 and Phe192 at the active cleft formed between them. We also found that the structural requirements of TCS to interact with the ribosomal stalk protein P2 C-terminal tail. The structural analyses suggest TCS attacks ribosomes by first binding to the C-terminal domain of ribosomal P protein. TCS exhibits a broad spectrum of biological and pharmacological activities including anti-tumor, anti-virus, and immune regulatory activities. This review summarizes an updated knowledge in the structural and functional studies and the mechanism of its multiple pharmacological effects.


1983 ◽  
Vol 134 (2) ◽  
pp. 151-164 ◽  
Author(s):  
P. Bruneau ◽  
B. Blondel ◽  
R. Crainic ◽  
F. Horodniceanu ◽  
M. Girard
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document